Research Article

MDM4 Isoform Expression in Melanoma Supports an Oncogenic Role for MDM4-A

Abdullah Alatawi,1 SoonJye Kho,2 and Michael P. Markey1

1Department of Biochemistry and Molecular Biology, Wright State University, Dayton, OH 45435, USA
2Department of Computer Science and Engineering, Wright State University, Dayton, OH 45435, USA

Correspondence should be addressed to Michael P. Markey; michael.markey@wright.edu

Received 30 August 2021; Revised 4 October 2021; Accepted 5 October 2021; Published 16 October 2021

Academic Editor: Nihal Ahmad

Copyright © 2021 Abdullah Alatawi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The p53 tumor suppressor integrates upstream signals such as DNA damage and active oncogenes to initiate cell cycle arrest or apoptosis. This response is critical to halting inappropriate growth signals. As such, p53 activity is lost in cancer. In melanoma, however, the p53 gene is intact in a reported 94% of human cases. Rather than direct mutation, p53 is held inactive through interaction with inhibitory proteins. Here, we examine the expression of the two primary inhibitors of p53, MDM2 and MDM4, in genomic databases and biopsy specimens. We find that MDM4 is frequently overexpressed. Moreover, changes in splicing of MDM4 occur frequently and early in melanomagenesis. These changes in splicing must be considered in the design of therapeutic inhibitors of the MDM2/4 proteins for melanoma.

1. Introduction

As it plays a critical role in the arrest of inappropriate cell growth, the p53 tumor suppressor gene (TP53) is mutated in approximately half of all human cancers [1]. In fact, it was mutational profiling of TP53 in squamous cell skin cancer that first implicated UV-induced dipyrimidine photoproducts as oncogenic [2]. However, it has been reported that TP53 is mutated in only 6% of melanomas [3]. Lying at a critical junction between DNA damage sensing and arrest or cell death, it is essential for a cancer cell to therefore find another way to repress the activity of p53. Commonly, this is through expression of the primary inhibitors of p53: MDM2 and MDM4. Both are able to bind to p53 and prevent its ability to transactivate target genes [4–7], but only MDM2 acts as a ubiquitin ligase to target p53 for proteasomal destruction [8–10]. On the contrary, MDM4 overexpression is observed in many cancers [11], including melanomas.

Ensembl contains at least 17 different transcripts derived from the MDM4 gene, five of which have level 1 evidence [12]. Interestingly, these transcripts result from alternative splicing which includes or excludes exons at different functional regions of the MDM4 gene. For example, the transcripts known as MDM4-211, MDM4-G, and MDM4-XALT2 all lack portions of the p53-binding domain while retaining the RING domain, through which MDM4 heterodimerizes with MDM2 [13–15]. Conversely, MDM4-S and MDM4-XALT1 retain the p53-binding domain but lack the RING domain [14–16]. Clearly, the biological impact of MDM4 overexpression will depend on which transcripts are being expressed. Despite the importance of MDM4 in melanoma, however, there has never been a systematic study of which transcripts are present in human melanomas.

2. Materials and Methods

Analysis of publicly available data: data were obtained from several public resources. Gene mutation frequency in melanoma was taken from the dataset SKCM-US, a 466-subject study of melanoma patients in the United States [17], and analyzed at the International Cancer Genome Consortium data portal [18]. The results published here are in whole or part based on data generated by the TCGA Research Network.
3. Results and Discussion

Genes mutated in melanomas were ranked in TCGA by frequency. The top 20 results are shown in Figure 1. Consistent with previous reports [3], most melanomas (87%) were found to retain an intact p53 gene. This emphasizes the need to repress p53 activity in these cancers. Therefore, we examined the frequency of amplification for both MDM2 and MDM4 in copy number data of TCGA melanomas versus normal controls (blood specimens). MDM2 copy number relative to controls is very similar (fold change: 1.099, \( p = 0.027 \)). In contrast, MDM4 was amplified both in greater magnitude (fold change: 1.148) and significance (\( p = 2.89 \times 10^{-7} \)) (Figure 2).

In order to determine if MDM4 amplification is likely to result in biologically significant expression changes, the expression of MDM4 was used to separate TCGA samples with survival data into two groups: those within the highest quartile of MDM4 expression and those in the lowest quartile. As shown in Figure 3, total MDM4 expression as measured here did not correlate with survival.

These expression data from TCGA suggest a selective advantage for the cancer to have higher MDM4 expression but fail to demonstrate a dramatic impact on patient survival. One possible reason for this is that the small reads of next-generation sequencing used to generate these data have difficulties distinguishing between the expression of different mRNA isoforms. Unless a read falls across a unique splice junction, it is difficult to assign it to a specific isoform by NGS. Analysis of splice junctions, therefore, was carried out in the Genotype-Tissue Expression (GTEx) data portal (Figure 4). Isoform-specific expression data for MDM4 in normal skin show a dramatic variation in expression between MDM4 isoforms. MDM4-211 [13, 14] was the most commonly observed isoform, more so than the full-length isoform. Other transcripts that currently exist only in Ensembl but not the cancer literature were also observed, such as MDM4-208, MDM4-201, and MDM4-206. There were no significant differences observed between sun-exposed and non-sun-exposed skin.

In order to compare these isoform expression data in normal skin to melanoma, the Patient-Derived Model Repository was queried for isoform-specific MDM4 expression (Figure 5). In these primary cultures of human melanomas, only two isoforms of MDM4 were identified in most samples: full-length mRNA (MDM4-FL) and MDM4-A.
MDM4-211 and MDM4-S were infrequently observed. Surprisingly, MFM4-A was significantly more common than any other isoform, including MDM4-FL (Figure 5(a)). For comparison, the same analysis was performed for the related gene MDM2. In contrast to MDM4, almost 100% of the samples expressed the full-length MDM2 isoform (Figure 5(b)). These NGS results were compared to isoform-specific RT-PCR for clinical melanoma and melanocytic nevi specimens. As in the NGS data, MDM4-A was the most frequently observed isoform. However, MDM4-S was also common. These differences are likely due to different methods used; RT-PCR for specific splice junctions is highly specific and will return a positive result with even low levels of target mRNA present. Interestingly, melanocytic nevi strongly resembled melanomas in their MDM4 isoform profiles. These data suggest that the splicing changes between normal skin (Figure 4) and melanomas (Figure 5) are already in place at the stage of nevi formation.

Studies of MDM4-S have recently suggested that the primary function of this splice variant is to decrease the levels of MDM4-FL by diverting pre-mRNA toward exon 9 skipping. The MDM4-S protein is rarely detectable without inhibition of proteasomal degradation [27]. Similarly, a protein product of MDM4-A has not been described in the literature. The transcript was first observed in the cervical cancer cell line C33a [28] and later described in gliomas [29]. Lacking the acidic domain, MDM4-A protein may be targeted by MDM2 for ubiquitination and degradation. In order to determine if MDM4-A mRNA expression is likely to have a biological impact in melanoma, TCGA samples with exon expression and survival data were analyzed based on the
inclusion of MDM4 exon 9 (chr1: 204512072–204515925) using the psichomics package in R (Figure 6). Skipping of exon 9 indicates MDM4-A. Of 345 subjects in the analysis, only 6.4% had at least 80% of their MDM4 reads skipping exon 9. However, these subjects had significantly lower survival ($p = 0.00472$).

Figure 3: MDM4 expression does not significantly correlate with patient survival. TCGA survival data for skin cutaneous melanoma were separated by the expression of MDM4. The "High" group (red) had the expression of MDM4 in the top 25% of available subjects. "Low" (blue) subjects were in the bottom 25% of expression for MDM4. $N$ for each group is 114 subjects. Kaplan–Meier analysis indicates no significant difference in survival between these groups; log-rank $p$ value = 0.247.

Figure 4: MDM4 isoform expression in normal skin. Non-sun-exposed (suprapubic) skin specimen data from 604 subjects and sun-exposed (lower leg) skin specimens from 701 subjects were analyzed in the GTEx data portal. Normalized reads $\times 100$ for each indicated isoform of MDM4 are displayed ($y$-axis). Isoforms are labeled using their common names or Ensembl numbers. Ensembl transcript evidence level 1 (TSL1) transcripts are in bold. *This Ensembl transcript (ENST00000470908.5) shares a name with the transcript commonly called MDM4-211 (ENST00000367183.7). **Two transcripts encode MDM4-S.
Figure 5: MDM4 isoform expression in melanocytic lesions is dramatically different from normal skin. Isoform-specific expression data were compared for 120 patient-derived xenografts. (a) Expression of the alternative transcript MDM4-A is significantly greater than the expression of the full-length MDM4 transcript in these specimens (Students’ t-test p value $= 1.386 \times 10^{-13}$). (b) In contrast, MDM2 expression is almost entirely the full-length transcript designated as MDM2-A. (c) Analysis of 30 clinical melanoma specimens and 10 melanocytic benign nevi by isoform-specific RT-PCR.

Figure 6: MDM4-A isoform correlates with poor survival. The subjects with an exon 9 percent spliced in (PSI) greater than 0.8 (indicating inclusion of exon 9 seen in $\geq 80\%$ of transcripts, $n = 323$) had significantly higher survival than subjects where $\geq 80\%$ of transcripts skipped exon 9 ($n = 22$, log-rank p value $= 0.00472$).

Figure 7: Model of melanomagenesis with the timeline of MDM2/4/p53 changes. Throughout progression from normal skin to metastatic disease, most cases retain wild-type p53 and demonstrate normal splicing and normal copy numbers of MDM2. In contrast, changes in MDM4 splicing are already in place in melanocytic nevi. MDM4 tends to be amplified in melanomas, and the profile of mRNA isoforms expressed is dramatically different from normal skin. This includes relatively high levels of MDM4-A.
4. Conclusions

Findings from TCGA skin cancer samples (Figure 1) are consistent with reports that p53 is mutated in only 6% of melanomas [3]. The tumor-suppressive activities of the p53 protein are therefore repressed by other means. MDM4 is known to be highly expressed in the skin [30]. We observed that MDM4 is amplified in melanomas, more so than the related protein MDM2 (Figure 2).

However, higher total expression of MDM4 did not correlate with melanoma patient survival in these TCGA data (Figure 3). We wanted to tease apart MDM4 isoform expression from total MDM4 expression. First, this was performed for expression data in normal skin, with and without sun exposure (Figure 4). These data present a surprising variety of MDM4 splice isoforms in normal skin, regardless of sun exposure. The MDM4-211 unique splice junction was observed most frequently, followed by MDM4-208 (ENST00000462012.1) and then MDM4-FL. When compared to data from short-term cultures of human melanomas, the pattern of MDM4 isoform expression is dramatically different (Figure 5(a)). By the time of clinical excision, MDM4-A has become the most common isoform. MDM4-211 and MDM4-S are rarely detected. This is consistent with the proposed role of MDM4-S in decreasing total MDM4-FL expression, allowing p53 activity. Similarly, a proposed role for MDM4-211 is the stabilization of MDM2. MDM4-211 retains the RING finger allowing binding to MDM2 whilst lacking the p53-binding domain. This stabilization of MDM2 may promote degradation of p53 [13]. These changes in MDM4 isoform expression had no parallels in MDM2 (Figure 5(b)). MDM4-A expression could be a consequence of the tumor culturing process used to generate the PDMR data. Therefore, isoform-specific RT-PCR was used to confirm the expression of MDM4-A in patient melanoma specimens, as well as in precancerous melanocytic nevi. The transition to MDM4-A expression may therefore represent an early event in melanogenesis (Figure 7).

As with MDM4-S, a splicing change need not result in the expression of a novel protein in order to have a biological impact [31]. The diversion of MDM4 pre-mRNA away from the full-length isoform and toward unstable isoforms such as MDM4-S could reduce total MDM4 protein available to inhibit p53, allowing MDM4-S to lead to p53 activation. However, we observe a negative impact of MDM4-A expression on survival, and this would suggest that MDM4-A does, in fact, result in the expression of an oncogenic protein. The expression of this protein remains to be demonstrated, along with a mechanism for this purported oncogenic activity.

Inhibiting MDM4 in melanoma arrests the cell cycle, and this is not rescued by the inhibition of p53 [32]. Therefore, altering the splicing of MDM4 toward unstable isoforms is an attractive target for therapy development. If the MDM4-A isoform is oncogenic in melanomas as suggested here, care must be taken to not shift alternative splicing toward this isoform.

Data Availability

The underlying data are presented within the manuscript itself, in the supplementary tables, or freely available within the databases referenced in the manuscript. These include the International Cancer Genome Consortium, The Cancer Genome Atlas, and the Genotype-Tissue Expression (GTEx) Project as indicated in Section 2.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors would like to acknowledge Dr. Nicolas Shamma, M. D., for kindly providing deidentified and blinded tissue specimens used to generate Figure 5(c). This research was funded by startup funds from the Laboratory of MPM.

Supplementary Materials

Supplementary Table 1: clinical diagnostic details of specimens used for RT-PCR analysis. Supplementary Table 2: PCR primers. (Supplementary Materials)

References

[1] E. H. Baugh, H. Ke, A. J. Levine, R. A. Bonneau, and C. S. Chan, “Why are there hotspot mutations in the TP53 gene in human cancers?” Cell Death & Differentiation, vol. 25, no. 1, pp. 154–160, 2018.
[2] D. E. Brash, J. A. Rudolph, J. A. Simon et al., “A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma,” Proceedings of the National Academy of Sciences, vol. 88, no. 22, pp. 10124–10128, 1991.
[3] P. Hainaut and G. P. Pfeifer, “Somatic TP53 mutations in the era of genome sequencing,” Cold Spring Harbor Perspectives in Medicine, vol. 6, no. 11, Article ID a026179, 2016.
[4] J. Momand, G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine, “The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation,” Cell, vol. 69, no. 7, pp. 1237–1245, 1992.
[5] J. D. Oliner, J. A. Pietenpol, S. Thiangalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein, “ Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53,” Nature, vol. 362, no. 6423, pp. 857–860, 1993.
[6] A. Shvarts, W. T. Steegenga, N. Riteco et al., “MDMX: a novel p53-binding protein with some functional properties of MDM2,” The EMBO Journal, vol. 15, no. 19, pp. 5349–5357, 1996.
[7] A. Shvarts, M. Bazuine, P. Dekker et al., “Isolation and identification of the human homolog of a new p53-binding protein, mdmx,” Genomics, vol. 43, no. 1, pp. 34–42, 1997.
[8] Y. Haupt, R. Maya, A. Kazaz, and M. Oren, “Mdm2 promotes the rapid degradation of p53,” Nature, vol. 387, no. 6630, pp. 296–299, 1997.
[9] R. Honda, H. Tanaka, and H. Yasuda, “Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53,” FEBS Letters, vol. 420, no. 1, pp. 25–27, 1997.
M. H. G. Kubbutat, S. N. Jones, and K. H. Vousden, “Regulation of p53 stability by Mdm2,” *Nature*, vol. 387, no. 6630, pp. 299–303, 1997.

F. Toledo and G. M. Wahl, “Regulating the p53 pathway: in vitro hypotheses, in vivo veritas,” *Nature Reviews Cancer*, vol. 6, no. 12, pp. 909–923, 2006.

“Gene: MDM4 (ENSG00000198625)—summary—homo_sapiens—ensembl genome browser 104,” 2021, http://useast.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000198625;r=chr1:204516379-204558120.

S. Giglio, F. Mancini, F. Gentiletti et al., “Identification of an aberrantly spliced form of hdmx in human tumors: a new mechanism for HDM2 stabilization,” *Cancer Research*, vol. 65, no. 21, pp. 9687–9694, 2005.

F. Mancini, G. Conza, and F. Moretti, “MDM4 (MDMX) and its transcript variants,” *Current Genomics*, vol. 10, no. 1, pp. 42–50, 2009.

D. S. Chandler, R. K. Singh, L. C. Caldwell, J. L. Bitler, and G. Lozano, “Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4,” *Cancer Research*, vol. 66, no. 19, pp. 9502–9508, 2006.

R. Rallapalli, G. Strachan, B. Cho, W. E. Mercer, and D. J. Hall, “A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity,” *Journal of Biological Chemistry*, vol. 274, no. 12, pp. 8299–8308, 1999.

Cancer Genome Atlas Network, “Genomic classification of cutaneous melanoma,” *Cell*, vol. 161, pp. 1681–1696, 2015.

Cancer Projects, “ICGC data portal,” 2021, https://dcc.icgc.org/projects?filters=%7B%22project%22:%7B%22id%22:%7B%22is%22:%5B%22SKCM-US%22%5D%7D%7D%7D.

D. R. Rhodes, J. Yu, K. Shanker et al., “ONCOMINE: a cancer microarray database and integrated data-mining platform,” *Neoplasia*, vol. 6, no. 1, pp. 1–6, 2004.

J. Anaya, “OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs,” *PeerJ Computer Science*, vol. 2, p. e67, 2016.

“GTEx portal,” 2021, https://www.gtexportal.org/home/.

“Patient-derived models repository (PDMR),” 2021, https://pdmr.cancer.gov/default.htm.

B. Langmead and S. L. Salzberg, “Fast gapped-read alignment with bowtie 2,” *Nature Methods*, vol. 9, no. 4, pp. 357–359, 2012.

J. K. Bonfield, J. Marshall, P. Danecek et al., “HTSlib: C library for reading/writing high-throughput sequencing data,” *GigaScience*, vol. 10, no. 2, Article ID giab007, 2021.

B. Li and C. N. Dewey, “RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome,” *BMC Bioinformatics*, vol. 12, no. 1, p. 323, 2011.

N. Saraiva-Agostinho and N. L. Barbosa-Morais, “Psichomics: graphical application for alternative splicing quantification and analysis,” *Nucleic Acids Research*, vol. 47, no. 2, p. e7, 2019.

B. Bardot and F. Toledo, “Targeting MDM4 splicing in cancers,” *Genes*, vol. 8, no. 2, p. 82, 2017.

P. de Graaf, N. A. Little, Y. F. M. Ramos, E. Meulmeester, S. J. F. Letteboer, and A. G. Jochenssen, “Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2,” *Journal of Biological Chemistry*, vol. 278, no. 40, pp. 38315–38324, 2003.

X. Wang, P. Sheng, X. Guo et al., “Identification and expression of a novel MDM4 splice variant in human glioma,” *Brain Research*, vol. 1537, pp. 260–266, 2013.

L. Fagerberg, B. M. Hallström, P. Oksvold et al., “Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics,” *Molecular & Cellular Proteomics*, vol. 13, no. 2, pp. 397–406, 2014.

B. Bardot and F. Toledo, “MDM4: don’t judge an isoform by its mRNA levels!” *Aging*, vol. 7, no. 10, pp. 744-745, 2015.

A. Gembarska, F. Luciani, C. Fedele et al., “MDM4 is a key therapeutic target in cutaneous melanoma,” *Nature Medicine*, vol. 18, no. 8, pp. 1239–1247, 2012.